Therapeutic area intelligence for Contraceptive with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

Teva →

Assets

AGILE →

Junel FE →

Recent signals(3)

RegulatoryJune 27, 2026

Teva's ANDA219324 for Junel FE Receives Approval Status from FDA

Teva Pharmaceuticals' ANDA219324 for Junel FE has received an Approval Pending (AP) status from the FDA.

RegulatoryJune 27, 2026

FDA Accepts Supplement Application for TWIRLA by AGILE

The FDA has accepted a supplemental application for TWIRLA, a contraceptive patch containing ethynyl estradiol and levonorgestrel.

RegulatoryJune 25, 2026

FDA Accepts Supplemental Application for TWIRLA

The FDA has accepted a supplemental application for TWIRLA, a contraceptive patch containing ethynyl estradiol and levonorgestrel.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.